Jubilant receives ANDA approval for Amlodipine and Olmesartan Medoxomil Tablets

Thursday, May 18, 2017

Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA)  final  approval  for Amlodipine  and  Olmesartan  Medoxomil  Tablets  5mg/20mg,  5mg/40mg,  10mg/20mg  and  10mg/40mg, the  generic  version  of  Azor®  of
Daiichi  Sankyo, which is used for the treatment of hypertension.

This is the third approval that we have received from the USFDA during the current financial year. As on December 31,  2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49have been approved.